Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria C Mazzarino

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cell Cycle (Georgetown, Tex.)|May 12, 2006
Absence of BRAF gene mutation in non-melanoma skin tumorsMassimo Libra, Grazia Malaponte, Valentina Bevelacqua, et al.
Oncotarget|August 30, 2012
Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanomaValentina Bevelacqua, Ylenia Bevelacqua, Saverio Candido, et al.
International Journal of Molecular Medicine|July 26, 2006
Long pentraxin 3: a marker of inflammation in untreated psoriatic patientsValentina Bevelacqua, Massimo Libra, Maria C Mazzarino, et al.
Oncology Reports|April 6, 2006
Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disordersMassimo Libra, Katia Mangano, Massimiliano Anzaldi, et al.
Journal of Neuroimmunology|May 12, 2005
Osteopontin gene haplotypes correlate with multiple sclerosis development and progressionAnnalisa Chiocchetti, Cristoforo Comi, Manuela Indelicato, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Aging|March 23, 2011
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S Steelman, William H Chappell, Stephen L Abrams, et al.
Oncotarget|March 18, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human healthWilliam H Chappell, Linda S Steelman, Jacquelyn M Long, et al.
Oncotarget|March 5, 2013
Advances in targeting signal transduction pathwaysJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cell Cycle (Georgetown, Tex.)|May 12, 2006
Absence of BRAF gene mutation in non-melanoma skin tumorsMassimo Libra, Grazia Malaponte, Valentina Bevelacqua, et al.
Oncotarget|August 30, 2012
Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanomaValentina Bevelacqua, Ylenia Bevelacqua, Saverio Candido, et al.
International Journal of Molecular Medicine|July 26, 2006
Long pentraxin 3: a marker of inflammation in untreated psoriatic patientsValentina Bevelacqua, Massimo Libra, Maria C Mazzarino, et al.
Oncology Reports|April 6, 2006
Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disordersMassimo Libra, Katia Mangano, Massimiliano Anzaldi, et al.
Journal of Neuroimmunology|May 12, 2005
Osteopontin gene haplotypes correlate with multiple sclerosis development and progressionAnnalisa Chiocchetti, Cristoforo Comi, Manuela Indelicato, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Aging|March 23, 2011
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S Steelman, William H Chappell, Stephen L Abrams, et al.
Oncotarget|March 18, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human healthWilliam H Chappell, Linda S Steelman, Jacquelyn M Long, et al.
Oncotarget|March 5, 2013
Advances in targeting signal transduction pathwaysJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Pageof 2